

Cover Story
Free
By Matthew Bin Han Ong
The proportion of racial and ethnic minority patients in NCI-funded clinical trials has nearly doubled over two decades—from 14% in 1999 to 25% in 2019, according to data from NCI's National Clinical Trials Network and the NCI Community Oncology Research Program.
In Brief
Clinical Roundup


Drugs & Targets


Trending Stories
- Christine Lovly to lead City of Hope’s new national thoracic oncology program
- FDA to remove black box warnings on hormone therapy for menopause
Trump-era “gold standard science” is not to be confused with gold standard of scientific evidence - Tidmarsh is out, Pazdur is in: FDA’s CDER under new leadership
- Rick Pazdur’s CDER appointment comes at exactly the right moment for FDA
- Smoldering multiple myeloma: Rethinking the waiting game
- Richard Pazdur, a respected insider with a plan to reengineer FDA, steps in as CDER director
















